Despite the frequent dysregulation of the PI3K pathway in gynecological cancers such as endometrial cancer (EC) and ovarian carcinoma (OC), PI3K pathway inhibitors have yet to show sufficient clinical efficacy for approval in these settings [4]. This evidence concerns the gene PIK3CA and ovarian carcinoma.